Pharmaceutical Companies are Changing Global Healthcare
Prior to the last decade, getting medicinal aid to poor countries in Africa was a challenge due to the high prices of disease-fighting drugs and the negligence of the pharmaceutical companies of the world, but there are some pharmaceutical companies changing global health care. Some drugs that helped combat deadly diseases like HIV, malaria and tuberculosis could have cost up to nearly $15,000 a year. The pharmaceutical companies in the past were more concerned with making a profit rather than saving the world’s poor. However, an incredible turnaround has occurred during the last decade and now as many as 20 million Africans have access to drugs and medicines to fight HIV, tuberculosis and malaria for as little as $100 per year.

The Change

Pharmaceutical companies began changing global health care about a decade ago when they experienced international backlash for their disregard for the struggling healthcare systems of the world’s poorest countries and their inability to combat diseases such as HIV/AIDS and malaria. This led to countries similar to South Africa legally suspending drug patents which allowed for small national companies in South Africa to begin producing cheaper alternatives to the highly expensive mainstream HIV drugs. Pharmaceutical companies dropped their lawsuits after the international backlash and instead decided to compete in these poor countries.

Competition Bred Change

The best way for many pharmaceutical companies to remain competitive in the global health care market is to cut their prices and sub-license their patents to generic drug makers. Price cuts have allowed for more than 400 drugs to sell cheaper than ever in Africa. Sub-licensing allows generic drug makers to temporarily have access to patents that pharmaceutical companies created, allowing them to cheaply and effectively create about 30 HIV/AIDS and Hepatitis C drugs over the last decade.

Newest Improvements

The most recent way that pharmaceutical companies are changing global health care is with the creation of Sanofi Global Health and their new brand Impact. Sanofi launched its nonprofit branch Sanofi Global Health in 2021 and dedicated its efforts to providing drug distribution and better healthcare implementation in the world’s poorest countries.

One of the most significant elements of Sanofi Global Health is Foundation S, which can fight childhood cancer in the poorest nations in the world, as well as increase health care access to populations that changing weather patterns most affect. The grandest aspect of Foundation S is the dedication to providing 100,000 free vials of treatment for patients with lysosomal storage disorders (LSD) every year.

The Most Significant Impacts

Sanofi Global Health just announced its new brand Impact on July 4, which promises to be one of the most influential announcements of the decade in terms of pharmaceutical companies changing global health care. Sanofi and Impact will target the poorest and most vulnerable regions of the world, providing 40 of the lowest-income countries with 30 Sanofi drugs and medicines. Among the medicines include insulin and treatment for tuberculosis, malaria and even cancer.

The Impact project also includes a fund for aiding startup companies in these poor countries so that the companies can one day provide sustainable health care within their own nation. This fund supports technical and financial applications of healthcare company innovation while working closely with other nonprofits to train healthcare professionals and increase investment in the healthcare industry.

Looking Ahead

The world’s poorest countries are certainly experiencing a never-before-seen increase in the quality of health care thanks to pharmaceutical companies and their commitment to changing global health care. With more than 40 countries receiving life-changing drugs and investments in their own health care systems, it is possible that this new age of global health care will change the lives of millions of the world’s poor.

Declan Harkness
Photo: Flickr

Pharmaceutical CompaniesBiopiracy, the act of expropriating a resource from a foreign land and profiting from it, has been a normal practice for pharmaceutical companies and governments for many years. Medicinal compounds with vital medicinal benefits stole from indigenous and impoverished areas without reparations/royalties in exchange. Invasive countries reap millions of dollars from biopiracy. In the process, they strip irreplaceable compounds from populations that fiercely depend on them. Many of these poorer countries lack the financial strength to fund analysis of plants for medicinal value. This analysis can widen the research gap between developing countries and the industrialized world even further. In an effort to reconcile these past injustices and inequalities, some pharmaceutical companies and research institutes have pledged funding to facilitate the growth of the medicinal drug industry in indigenous areas.

Berkeley and Samoa

In 2004, the University of California at Berkeley struck a deal with the government of Samoa, a small Pacific Ocean island nation. The university will share royalties from the highly revolutionary and precious compound prostratin, native to the Samoan mamala trees. It was discovered the drug was effective in treating HIV/AIDS by flushing the virus out of reservoirs in the body. The university pledged to equally split all revenues generated from the drug. It was used commonly on the island to treat hepatitis. After isolating the genes responsible for producing the drug in the tree, the researchers were able to carry out microbial production.

National Cancer Institute and Samoa

Three years prior, the National Cancer Institute (NCI) issued a license to the AIDS Research Alliance (ARA) to conduct research on the drug prostratin. The NCI exclusively patented this. The methodology behind the research is significantly different from Berkeley’s, as it does not rely on gene sequencing. The percentage of total royalties returned to the island is 20%. This is much lower than the charitable cut Berkeley would offer in the future.

However, this partnership was highly influential in staging the blueprint for American companies to share their copious wealth with the lands they took from. Much of the revenue returning to Samoa continues to be funneled into villages. In addition, it provides healers on the island with more sophisticated equipment and labs. In congruence with the deal, there will be over $500,000 of combined value to the construct water tanks, a medical clinic, three schools, a trail system and a tourist walkway from which the village would keep all revenue.

Merck & Co. and Costa Rica

In 1991, Merck & Co. is one of the pharmaceutical companies that sought to turn obscure compounds into gainful products in the agriculture and pharmaceutical markets. It extended a two-year deal to the nonprofit biodiversity institute in Costa Rica INBio. This entailed the exchange of plant and insect samples for $1 million. This was a mutually beneficial investment. Costa Rica was looking for donors in the private sector to help preserve its tropical and sub-tropical forests. There are ethical concerns surrounding the usage of said investment in building more commercially viable tourist attractions instead of natural preserves. However, regardless of Costa Rica’s money management, the company’s investment was nothing short of magnanimous.

ICBG and Coiba

The island of Coiba, 12 miles off the coast of Panama, was designated as a national park in 1991. It drew much interest in its coral reefs in 2005 when scientific research suggested that they contained an abundance of new species with medicinal and commercial potential. By far, the most promising discovery was octocoral, from which anti-malarial properties can be extracted. Following these exciting developments, the International Co-Operative Biodiversity Groups (ICBG) invested millions in building scientific infrastructure on the mainland of Panama. For instance, testing and processing sites for potential medicinal compounds.

The collaboration pledged to distill at least half of all profits into trust funds. The trust funds design to protect Coiba from internal and external environmental hazards. The profit will also go to the institutions that aided the project. A biological research station was built on the island. The security systems programmed will eradicate colonists and fisherman that could disrupt the ecosystem. ICBG has been successful in identifying and analyzing medicinal compounds in many other countries including Suriname, Vietnam and Madagascar.

These examples of corporations reconciling past exploitation of resources are certainly worth celebrating. However, there is work left to do. Pharmaceutical companies fund indigenous communities and spurring growth of their medicinal industries is still the minority. There is damage that has been left unrectified. These communities rely heavily on the resources insular to their area and supported by a well-funded and functioning infrastructure. In the fight to end global poverty, one of the first places to start is in the coniferous islands and peninsulas. It was once abundant in medicinal compounds but has since been plundered. It is important that the people in these areas can live healthy lives and benefit from the rich resources native to their land.

Camden Gilreath
Photo: Flickr

On April 1, 2014, The World Bank, the Bill and Melinda Gates Foundation, and the Children’s Investment Fund Foundation pledged $240 million to fight “neglected” infectious diseases in Africa and other developing regions. The funds are in conjunction with a 2012 pledge from 13 pharmaceutical companies and the governments of the United States, the United Arab Emirates, and the United Kingdom that promised monetary and medicinal donations to treat and possibly cure 10 of the most virulent parasitic and bacterial infections by the end of the decade.

Donated medicines will target rabies, leprosy, blinding trachoma, chagas disease, endemic treponematoses (yaws), onchocerciasis (river blindness), dracunculiasis (guinea worm), visceral leishmaniasis (the second highest parasitic killer after malaria), schistosomiasis (bilharziasis), lymphatic filariasis (elephantiasis), and Human African trypanosomiasis (sleeping sickness). The targeted diseases afflict one in six people globally.

When deciding which diseases on which to focus, the Bill and Melinda Gates Foundation looked at the diseases’ scale and gravity, the burdens that the diseases exact on developing nations, and how great the chance is that the diseases could be managed or eradicated.

The Bill and Melinda Gates Foundation and the Children’s Investment Fund Foundation will each donate $50 million and the World Bank will give $120 million.

This partnership between large donors and pharmaceutical companies is an attempt to maximize the effectiveness of the renewed effort to treat and eradicate neglected infectious diseases.

A large proportion of the donated money, $120 million, will be used to fight soil-transmitted helminthes, including hookworm, roundworm and whipworm. These intestinal worms are some of the most common afflictions for children in the developing world.

The partners aim to aggressively address these diseases through widespread drug administration, public health data collection, and vector control.

Administration of drugs will be facilitated by the mass donation of drugs from pharmaceutical companies and coordination efforts to treat multiple infections with similar methods. Data collection is critical, especially for traditionally neglected diseases, in order to know the prevalence of infection in humans and in the vectors that transmit it. Because the vectors that spread infectious diseases are costly and challenging to control, the partner organizations see potential in “cross-disease coordination” to maximize the impact of vector-control efforts.

According to the Bill and Melinda Gates Foundation, more than 1 billion people in the developing world contract infectious diseases that are often neglected and receive less funding from international donors.

These neglected infectious diseases can cause death, blindness, anemia, pregnancy complications, brain damage and stunting of children’s growth. Many of those afflicted suffer from more than one of these diseases simultaneously, which not only affects people’s health but also their ability to go to work or school, take care of their family and create their personal paths out of poverty.

The director-general of the World Health Organization (WHO), Margaret Chan, asserts that partnerships with pharmaceutical companies that have donated large amounts of drugs have already led to “tremendous progress.”

Further, she states, “Together with the governments of endemic countries, we are fast approaching the goal of controlling or eliminating many of these ancient causes of human misery.”

– Kaylie Cordingley

Sources: Science Report, Reuters, Gates Foundation
Photo: Science Report